Design Therapeutics Inc.

NASDAQ: DSGN · Real-Time Price · USD
3.24
-0.33 (-9.24%)
At close: May 14, 2025, 3:34 PM

Design Therapeutics Statistics

Share Statistics

Design Therapeutics has 56.77M shares outstanding. The number of shares has increased by 0.47% in one year.

Shares Outstanding 56.77M
Shares Change (YoY) 0.47%
Shares Change (QoQ) 0.25%
Owned by Institutions (%) 99.99%
Shares Floating n/a
Failed to Deliver (FTD) Shares 184
FTD / Avg. Volume 0.12%

Short Selling Information

The latest short interest is 3.54M, so 6.23% of the outstanding shares have been sold short.

Short Interest 3.54M
Short % of Shares Out 6.23%
Short % of Float 9.44%
Short Ratio (days to cover) 27.77

Valuation Ratios

The PE ratio is -7.04 and the forward PE ratio is -3.23. Design Therapeutics's PEG ratio is 0.27.

PE Ratio -7.04
Forward PE -3.23
PS Ratio 0
Forward PS 3.8
PB Ratio 1.44
P/FCF Ratio -8.04
PEG Ratio 0.27
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Design Therapeutics.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 29.31, with a Debt / Equity ratio of 0.01.

Current Ratio 29.31
Quick Ratio 29.31
Debt / Equity 0.01
Debt / EBITDA -0.05
Debt / FCF -0.05
Interest Coverage 0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee n/a
Profits Per Employee $-885,500
Employee Count 56
Asset Turnover 0
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate 0%

Stock Price Statistics

The stock price has increased by -20.04% in the last 52 weeks. The beta is 1.78, so Design Therapeutics's price volatility has been higher than the market average.

Beta 1.78
52-Week Price Change -20.04%
50-Day Moving Average 4.1
200-Day Moving Average 4.98
Relative Strength Index (RSI) 44.29
Average Volume (20 Days) 151,570

Income Statement

Revenue n/a
Gross Profit n/a
Operating Income -62.38M
Net Income -49.59M
EBITDA -48.99M
EBIT n/a
Earnings Per Share (EPS) -0.88
Full Income Statement

Balance Sheet

The company has 22.56M in cash and 2.33M in debt, giving a net cash position of 20.23M.

Cash & Cash Equivalents 22.56M
Total Debt 2.33M
Net Cash 20.23M
Retained Earnings -227.21M
Total Assets 252.09M
Working Capital 239.58M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -43.1M and capital expenditures -340K, giving a free cash flow of -43.45M.

Operating Cash Flow -43.1M
Capital Expenditures -340K
Free Cash Flow -43.45M
FCF Per Share -0.77
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

DSGN does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for DSGN is $4, which is 11.4% higher than the current price. The consensus rating is "Hold".

Price Target $4
Price Target Difference 11.4%
Analyst Consensus Hold
Analyst Count 1
Stock Forecasts

Scores

Altman Z-Score 13.92
Piotroski F-Score 2